CYTR - CytRx highlights positive data from phase 2 QUILT 88 trials in pancreatic cancer patients

Biopharmaceutical company CytRx (CYTR) says that NantKwest and ImmunityBio's ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates.Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer. There are currently no FDA approved treatment for the indication.In the Cancer Moonshot QUILT trials of haNK combined with PD-L1 inhibitor avelumab, which were completed in 2019, the median overall survival rate more than doubled (three months historic control versus 8 months in the treatment arm) in the 12-patient trial.

For further details see:

CytRx highlights positive data from phase 2 QUILT 88 trials in pancreatic cancer patients